Diagnosis & Treatment
Bowel cancer is Australia's second biggest cancer killer and affects 1 in 12 Australians in their lifetime. So chances are that you, or someone you know, will be affected in some way by the disease.
Bowel Cancer Australia champions what matters most to people affected by bowel cancer and empowers them with the tools and knowledge to be advocates for their own health.
Timely Access to Colonoscopy
Bowel Cancer Australia advocates for prompt access to diagnostic colonoscopy.
Clinically significant symptoms, such as rectal bleeding, require investigation via colonoscopy within 30 days.
Similarly, a positive faecal immunochemical test (FIT) / faecal occult blood test (FOBT) means blood, invisible to the naked eye, has been detected in the bowel movement which requires further investigation via colonscopy within 30 days.
Timely Access to Surgery
New data released in October 2014 on the Federal Government's My Hospitals
website shows most bowel cancer patients (88%) on the public hospital waiting list receive their surgery within the recommended 30 days.
However the data does not tell the whole story for bowel cancer patients - with no information available in the report on private hospital waiting times.
The National Health Performance Authority's (NHPA) report into Hospital Performance: cancer surgery waiting times in public hospitals in 2012-13 covers bowel, lung and breast cancer - three of the most common malignant cancers.
Inaugural global standard in bowel cancer patient care
Bowel cancer patients are one step closer to a world-first standard in care thanks to an international collaboration between Bowel Cancer Australia and the International Consortium for Health Outcomes Measurement (ICHOM).
Bowel Cancer Australia's sponsorship will support the ICHOM Colorectal Cancer Working Group, which brings together an international team, including Australian health professionals, clinicians and patients, to help establish the global standard.
Alliance for Safe Biologic Medicines
Formed in 2010, the Alliance aims to ensure patient safety is at the forefront of biosimilar policy discussions, by communicating the perspectives of patients and their healthcare providers.
The Alliance consists of physicians, patients, pharmacists, researchers and manufacturers of both boiologic and biosimilar medicines, working together to promote their safe use globally.
Additionall, the Alliance is working to ensure physicians and patients remain in charge of their treatment decisions; that biosimilars are held to safety and efficacy standards comparable to their precedessors; and that physicians are informed whenever a biosimilar substitution occurs. Read More
My Cancer. My Voice.
Bowel Cancer Australia is calling on the Federal Government to urgently address concerning inequities in support and access to life-extending treatments for Australia's second deadliest cancer.
The call comes in the wake of results from the first national patient survey of its kind, released to mark the start of Bowel Cancer Awareness Month in June 2014, which shows Aussies with bowel cancer feel like they have the 'wrong cancer' due to lack of dedicated support services and low awareness.
Australian Cancer Consumer Network
The Australian Cancer Consumer Network (ACCN) was launched at Parliament House in November 2014, forming the first time an umbrella organisation to represent cancer consumer groups.
The ACCN unites 30 cancer consumer groups for a bigger voice as well as to share information, experiences and action techniques. It is facilitated by Cancer Voices Australia.
Clinical Practice Guidelines
Bowel Cancer Australia affiliated gastroenterologists, including Dr Cameron Bell - Chair of the Colonoscopy Surveillance Working Group, have contributed to the development of the National Health and Medical Research Council (NHMRC) Clinical Practice Guidelines for Surveillance Colonoscopy.
Dr Cameron Bell said the guidelines are intended for use by all practitioners and health workers who require information about surveillance colonoscopy in adenoma follow-up, following curative resection of bowel (colorectal) cancer, and for cancer surveillance in inflammatory bowel disease.